Premium
Specifications for anti‐A and anti‐B in intravenous immunoglobulin: history and rationale
Author(s) -
Thorpe Susan J.
Publication year - 2015
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.13091
Subject(s) - hemolysis , medicine , antibody , adverse effect , titer , immunology , immunoglobulin g , pharmacology
Intravenous immunoglobulin (IVIG) products are generally safe and efficacious, although treatment‐related adverse reactions can occur in recipients. Adverse reactions include hemolysis in non–blood group O recipients linked to the passive transfer of anti‐A and/or anti‐B present in the fractionated immunoglobulin product. In light of the recent increase in reported cases of severe hemolysis associated with anti‐A and/or anti‐B, this article traces the development of pharmacopoeial specifications, tests, and reference reagents to control their titers in IVIG products.